サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび/またはその誘導体の使用方法

Japanese Patent JP2004528307

A

This invention is directed to a method of using a therapeutic composition comprising an ester of an alpha-ketoalkanoic acid for the treatment of cytokine-mediated inflammatory conditions. The cytokine-mediated inflammatory conditions are mediated by, for example, Tumor Necrosis Factor (TNF), interleukin-1beta (IL-1beta)) or High Mobility Group B-1 (HMGB-1) mediator of inflammation. Exemplary cytokine-mediated inflammatory conditions include, but are not limited to, rheumatoid spondylitis, osteoarthritis, gouty arthritis, endotoxic shock, cerebral malaria, silicosis, pulmonary sarcoidosis, bone resorption disease, graft versus host disease, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), Crohn's disease, rheumatoid arthritis, cachexia and septic shock.

Fink Mitchell Pea.
Ulyoa Lewis
Tracy Kevin Jay.

JP2002573009A

September 16, 2004

March 15, 2002

Click for automatic bibliography generation  

UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

A61K47/02; A61K31/16; A61K31/19; A61K31/22; A61P1/04; A61P7/00; A61P11/06; A61P17/00; A61P17/06; A61P19/02; A61P29/00; (IPC1-7): A61K31/22; A61K31/16; A61K31/19; A61K47/02; A61P1/04; A61P7/00; A61P11/06; A61P17/00; A61P17/06; A61P19/02; A61P29/00

JPS5739260B2	1982-08-20
JPH09512741A	1997-12-22
JP2003510357A	2003-03-18

US4234599A	1980-11-18
US4197316A	1980-04-08
US4246261A	1981-01-20
US2307075A	1943-01-05

JPN6008055131, ＣＲＥＳＴＡＮＥＬＬＯ，Ｊ．Ａ．　ｅｔ　ａｌ，　Ｐｙｒｕｖａｔｅ　ｉｍｐｒｏｖｅｓ　ｍｙｏｃａｒｄｉａｌ　ｔｏｌｅｒａｎｃｅ　ｔｏ　ｒｅｐｅｒｆｕｓｉｏｎ　ｉｎｊｕｒｙ　ｂｙ　ａｃｔｉｎｇ　ａｓ　ａｎ
JPN6008055132, ＤＥＢＯＥＲ，Ｌ．Ｗ．　ｅｔ　ａｌ，　Ｐｙｒｕｖａｔｅ　ｅｎｈａｎｃｅｓ　ｒｅｃｏｖｅｒｙ　ｏｆ　ｒａｔ　ｈｅａｒｔｓ　ａｆｔｅｒ　ｉｓｃｈｅｍｉａ　ａｎｄ　ｒｅｐｅｒｆｕｓｉｏｎ　ｂｙ　ｐｒｅｖｅｎ
JPN6008055133, ＧＨＡＮＤＯＵＲ，　ＭＡ　ｅｔ　ａｌ，　Ｊ　Ｉｎｄｉａｎ　Ｃｈｅｍ　Ｓｏｃ，　１９８８，　Ｖｏｌ．６５，　Ｎｏ．１０，　ｐ．７１６−８

Hatsushi Shimizu
Kazunori Hashimoto

Previous Patent: ビス−トリフルイミド化合物に触媒される方法

Next Patent: 脂質プロフィールのモジュレーション